advertisement
Editorial IGR 2-1
Dear Reader,
This issue of IGR, the first covering papers from the new millennium, makes its appearance on the occasion of the millennium meeting of the EGS, its sixth congress and (more than) 20th anniversary.
The EGS was founded in 1979 and had its first congress 20 years ago, in 1980, also in the UK (organizer, Redmond Smith). A true celebration in London, June 2000, of the grown-up (20-year-old!) EGS. In fact, this celebration has attracted more than a thousand participants at the time of writing this editorial. A nice birthday present!
Since the last issue of IGR (I/3), a number of glaucoma meetings have been held. The reader will find reports of glaucoma at ARVO (pointwise ARVO TOP-10), the Gullstrand meeting, the meeting of the ANZGC (Expert), the meeting of the AGS (Expert), and LAGS (Expert) in this issue. Furthermore, there will be announcements of several forthcoming glaucoma meetings.
The two Awardees receiving the IGR Award 1999 have been duly selected by the selection committee after the nomination of ten papers by the nomination committee (see website). The Awardees, Ron Harwerth and the collaborators Francesca Cordeiro and Peng Khaw, are congratulated on this choice by the World's Glaucoma Societies. The recognition of innovative thoughts put into practice, involving blood, sweat, and tears (page 10). All those present at the Gala dinner of the EGS Millennium meeting will be able to witness the Award ceremony.
During ARVO, the Proctor medal was presented to Laszlo Bito and Johan Stjernschantzfor the development of latanoprost. Again, many congratulations. Patients and doctors are happily making use of the result of this development.
IGR is continuing its project to stimulate companies to present EBA (evidence based advertising: ads on left page and scientific evidence on the right). A novel effort that has now found the support of three companies who are willing and able to show that they indeed have the evidence.
The reader's attention is drawn to several papers, mostly reviews and editorials, that have particularly impressed the editor. The abstract alone does not do them justice. Recommended reading.
The Editor's Selection covers a variety of papers that deal with the pathogenesis of glaucoma, astrocytes, the neurotrophic factor, ischemia, which cell goes first, etc.; we know more and more about the functioning of the trabecular meshwork; several papers deal with progression and its risk factors; cytoskeleton drugs are being developed; iris changes after latanoprost are discussed; not to overtreat with laser trabeculoplasty; new forms of antifibrotic treatment have been developed.
This should be enough. Bless the reader who reads it all and remembers it! Good luck.
E.L. Greve
